SEC 13F Intelligence

Managers / Q1 2021 · view latest →

Gates Foundation

CIK 0001663801 · 500 5TH AVE NORTH, SEATTLE, WA, 98109 · 206-709-3100

Reported Value
$656M
Q1 2021
Positions
7
Filings on Record
19
2019–present window
Filed
May 14, 2021
original filing

Summary

Gates Foundation reported $656M in U.S.-listed holdings across 7 positions for Q1 2021.

The portfolio is heavily concentrated: Curevac N V alone accounts for 43.7% of reported value.

Compared with Q4 2020, the fund opened 2 new positions and exited 0.

Portfolio Metrics

Turnover
+0.3%
vs prior filed quarter
Largest Position
+43.7%
Curevac N V

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’20: $438MQ4 ’20Q1 ’21: $656MQ2 ’21: $692MQ2 ’21Q3 ’21: $342MQ4 ’21: $330MQ4 ’21Q1 ’22: $186MQ2 ’22: $130MQ2 ’22Q3 ’22: $127MQ4 ’22: $130MQ4 ’22Q1 ’23: $113MQ2 ’23: $126MQ2 ’23Q3 ’23: $84MQ4 ’23: $90MQ4 ’23Q1 ’24: $84MQ2 ’24: $60MQ2 ’24Q3 ’24: $44Mfilingsflow.com

Portfolio Composition

By security type
Other: 43.7%Common Stock: 28.4%ADR: 27.9%
  • Other · 43.7% · $287M
  • Common Stock · 28.4% · $186M
  • ADR · 27.9% · $183M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
IMCRIMMUNCORE HLDGS PLCNEW+1.63M1.63M+$69M$69M
BFLYBUTTERFLY NETWORK INCNEW+1.01M1.01M+$17M$17M
VIRVIR BIOTECHNOLOGY INCHELD+02.78M+$68M$142M
CUREVAC N VHELD+03.13M+$33M$287M
BNTXBIONTECH SEHELD+01.04M+$28M$113M
AMYRIS INCHELD+0292.4K+$4M$6M
ATRECA INCHELD+01.40M$2M$21M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2021

7 positions
#IssuerClass% PortfolioValueShares
1CUREVAC N VCOM43.71%$287M3.13M
2VIRVIR BIOTECHNOLOGY INChistory →COM21.71%$142M2.78M
3BNTXBIONTECH SEhistory →SPONSORED ADS17.29%$113M1.04M
4IMCRIMMUNCORE HLDGS PLChistory →ADS10.58%$69M1.63M
5ATRECA INCCL A COM3.26%$21M1.40M
6BFLYBUTTERFLY NETWORK INChistory →CL A COM2.59%$17M1.01M
7AMYRIS INCCOM NEW0.85%$6M292.4K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2024$44M5Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$60M6Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$84M8May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$90M8Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$84M9Nov 13, 202313F-HRchanges · EDGAR ↗
Q2 2023$126M9Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$113M9May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022$130M9Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$127M10Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$130M9Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$186M11May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$330M11Feb 11, 202213F-HRchanges · EDGAR ↗
Q3 2021$342M10Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$692M8Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$656M7May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$438M5Feb 16, 202113F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.